Table 2.
Objective tumor response
| Best overall response | East Asian |
Non-East Asian |
||
|---|---|---|---|---|
| Docetaxel+ramucirumab combination treatment (n=43) | Docetaxel (docetaxel+placebo) (n=46) | Docetaxel+ramucirumab combination treatment (n=585) | Docetaxel (docetaxel+placebo) (n=579) | |
| Complete response | 0 | 0 | 3 (0.5) | 2 (0.3) |
| Partial response | 11 (25.6) | 4 (8.7) | 130 (22.2) | 79 (13.6) |
| Stable disease | 19 (44.2) | 19 (41.3) | 239 (40.9) | 225 (38.9) |
| Objective response | 11 (25.6) | 4 (8.7) | 133 (22.7) | 81 (14.0) |
| 95% CI | 13.5-41.2 | 2.4-20.8 | 19.4-26.3 | 11.3-17.1 |
| Disease control ratea) | 30 (69.8) | 23 (50.0) | 372 (63.6) | 306 (52.8) |
| 95% CI | 53.9-82.8 | 34.9-65.1 | 59.5-67.5 | 48.7-57.0 |
Values are presented as number (%) unless otherwise indicated. CI, confidence interval.
a)
Denotes best response for complete response, partial response, or stable disease.